Search Medical Condition
Please enter condition
Please choose location from dropdown

Lexington, Kentucky Clinical Trials

A listing of Lexington, Kentucky clinical trials actively recruiting patient volunteers.

RESULTS

Found (596) clinical trials

Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as maintenance therapy for up to 12 cycles) on event-free survival in subjects with FLT3-internal tandem duplication ...

Phase

1.58 miles

Learn More »

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.

The purpose of this study is to evaluate the efficacy and safety of a single transendocardial delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in clinical outcomes (HF-MACE), preventing further adverse cardiac remodeling (LVESV and LVEDV), and increasing exercise capacity (6MWT) in patients ...

Phase

1.58 miles

Learn More »

Researchers at the University of Kentucky are inviting you to participate in a study investigating a new noninvasive technique to measure blood flow in the eye.

Phase N/A

1.58 miles

Learn More »

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. To compare disease-free survival (DFS) of standard risk pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone. SECONDARY OBJECTIVES: I. To determine ...

Phase

1.58 miles

Learn More »

You screen their Internet access. You screen their movies. Have you screened their blood for increased risk of Type 1 diabetes? A blood test can identify risk for type 1 diabetes up to 10 years before symptoms appear. This test is offered at no cost to people who have a ...

Phase N/A

1.58 miles

Learn More »

Researchers at the University of Kentucky are inviting you to participate in a 12-week exercise program to better understand how exercise could be used most effectively to promote weight control. Participants will be compensated $150 for their time. For more information, please contact: Dr. Kyle Flack kyle.flack@uky.edu 859-257-4351

1.58 miles

Learn More »

Our Research Center, with Crestovo (a pharmaceutical company), is seeking volunteers to participate in a clinical research study to prevent recurrent Clostridium difficile (C. difficile). To find out more about this study, and about how to get involved, please contact: Beth Plummer at 859-323-5893

Phase N/A

1.58 miles

Learn More »

Researchers are conducting a study to explore factors that affect gay men's satisfaction with health care interaction in the state of Washington. Participants will be asked to complete an Internet-based survey, which is estimated to take between 24 and 36 minutes. For more information, please contact: Michael Huggins, EdD ARNP ...

Phase N/A

1.58 miles

Learn More »

Researchers at the University of Kentucky College of Health Sciences need participants as a part of a study they are conducting. Testing involves a one time throat examination and voice quality measures. You would need to come in one time for an hour and six times for less than 30 ...

Phase N/A

1.58 miles

Learn More »

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

PRIMARY OBJECTIVES: I. To determine the objective response rate to trametinib in children with recurrent or refractory juvenile myelomonocytic leukemia (JMML). SECONDARY OBJECTIVES: I. To further define and describe the toxicities of single agent trametinib in children with recurrent or refractory JMML. II. To further characterize the pharmacokinetics of trametinib ...

Phase

1.58 miles

Learn More »